Fertility and Endocrinology Unit, Department of Gynecology and Obstetrics, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark.
Acta Obstet Gynecol Scand. 2012 Nov;91(11):1252-60. doi: 10.1111/j.1600-0412.2012.01471.x.
Anti-Müllerian hormone (AMH) plasma levels reflect the continuous non-cyclic growth of small follicles, thereby mirroring the size of the resting primordial follicle pool and thus acting as a useful marker of ovarian reserve. Anti-Müllerian hormone seems to be the best endocrine marker for assessing the age-related decline of the ovarian pool in healthy women; thus, it has a potential ability to predict future reproductive lifespan. The most established role for AMH measurements is before in vitro fertilization is initiated, because AMH can be predictive of the ovarian response, namely poor and hyper-responses. However, recent research has also highlighted the use of AMH in a variety of ovarian pathological conditions, including polycystic ovary syndrome, granulosa cell tumors and premature ovarian failure. A new commercial enzyme-linked immunosorbent assay for measuring AMH levels has been developed, making results from different studies more comparable. Nevertheless, widespread clinical application awaits an international standard for AMH, so that results using future assays can be reliably compared.
抗苗勒管激素（AMH）的血浆水平反映了小卵泡的持续非周期性生长，从而反映了静止原始卵泡池的大小，因此可作为卵巢储备的有用标志物。抗苗勒管激素似乎是评估健康女性卵巢池与年龄相关的下降的最佳内分泌标志物；因此，它具有预测未来生殖寿命的潜力。AMH 检测的最主要作用是在开始体外受精之前，因为 AMH 可以预测卵巢反应，即卵巢反应不良和超敏反应。然而，最近的研究还强调了 AMH 在各种卵巢病理情况下的应用，包括多囊卵巢综合征、颗粒细胞瘤和卵巢早衰。一种新的用于测量 AMH 水平的商业酶联免疫吸附测定法已经开发出来，使不同研究的结果更加可比。然而，广泛的临床应用需要 AMH 的国际标准，以便能够可靠地比较未来检测结果。
